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Introduction
Robust biorepositories with readily available, high-quality, and 
well-annotated biospecimens play an essential role in advanc-
ing cancer research and personalized medicine.1,2 According to 
the biological material tracking recommendations of the 
International Society for Biological and Environmental 
Repositories (ISBER) and National Cancer Institute (NCI) 
Best Practices, biorepository information systems are expected 
to handle specimen tracking and have full query capability 
across all data stored. Both emphasize that biorepository infor-
mation systems should consolidate data from different local 
systems within the institution (electronic medical records, can-
cer registries, pathology systems, etc)3,4 Biorepositories use 
databases that have 2 main components: an inventory system 
with compiled clinical information from different data sources 
and a link to samples in the physical repository. The inventory 
system enables administrators to retrieve on demand any 
requested clinical and diagnostic data on specific patients.5-8
Biospecimen Repository Core Facility (BRCF) plays a vital 
role at University of Kansas Medical Center (KUMC). Its eth-
ical collection, storage, annotation, and distribution of high-
quality biospecimens are essential to support translational 
research and investigator-initiated studies.
The BRCF was established in 1993 as breast tissue and 
serum repository. In 2011, changes were implemented to store 
bodily fluids (whole blood, urine, and saliva) with matching 
tumor. In addition, the BRCF launched the Early Detection 
Screening Project (EDSP) in 2013. This project is focused on 
collecting blood samples from women undergoing mammog-
raphy screening and tracks changes in their medical history. 
The number of participants registered with the BRCF has 
grown by an average of 38% each year. In 2017, over 3700 par-
ticipants consented to specimen collection and the BRCF col-
lected solid tissue and blood samples at over 5800 patient 
visits.
In 2017, C3OD was launched to address the lack of uni-
formity in clinical data collection and to create a unified system 
for the clinical annotation of the increasing number of speci-
mens available to KUCC scientists for cancer research. C3OD 
merges data from the electronic medical record, the tumor reg-
istry, the biospecimen database, and the data registry to allow 
queries within a unified platform.9 The C3OD has 2 databases, 
identified and de-identified databases, to protect protected 
health information. This database extracts data from tumor 
registry with “NAACCR 16C” (tumor anatomic site, histology, 
etc), EMR (demographics, family history, diagnosis, comor-
bidities, etc), and biospecimen inventory information (sample 
type, annotation, the location of the sample within the freezer, 
etc). The 3 databases are populated in 3 stages: the extraction 
stage creates user-friendly querying (eg, gender is recorded into 
f/m/unknown from original 1/2/3), the transformation stage, 
and finally, the loading stage. The loaded data is also validated 
by the informatics administrator. This preparation and clean-
ing process takes about 2 weeks as the process is time-consum-
ing. To be cost effective, the data refresh occurs once a month. 
Architecture is described in Figure 1: initial C3OD database 
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architecture has been enhanced with biospecimen data being 
merged using the patient medical record number. The BRCF 
utilizes an inventory management system called OpenSpecimen 
developed by Krishagni (https://www.openspecimen.org/). 
Within the OpenSpecimen system, high-level patient infor-
mation is being captured (medical record number, date of birth, 
patient name, gender) along with detailed information of the 
collection visit (sample type, sample class, quantity, collected by, 
collection date/time, pathology status, anatomic site, laterality, 
storage location). Variables used from tumor registry and bio-
specimen repository to populate C3OD are found in the 
Supplementary File 1. In this short report, we introduce the 
process and results of the BRCF operations utilizing C3OD, 
provide demonstrations of several examples, and discuss future 
directions for the BRCF.
Materials and Methods
C3OD facilitates translational cancer research. Once a 
researcher obtains IRB and Data Access Committee (DAC) 
approvals, they can obtain patients’ protected health informa-
tion. There are 3 major components involved in this process: 
the Kansas Cancer Registry houses data pertaining to cancer 
incidence information in the State of Kansas; the biospecimen 
repository (BRCF) collects, stores, and manages specimens of 
the cancer patients; and the Biostatistics and Informatics 
Shared Resource (BISR) provides statistical, data science, and 
informatics support to all cancer researchers. Each component 
nominates a representative to the DAC. The BRCF follows 
best practices in biospecimen storage and data management. 
Standard operating procedures, covering topics such as patient 
consent, specimen storage, and data management, have been 
developed to govern these processes. The BRCF preserves 
fresh and frozen tissue samples (both tumor and adjacent nor-
mal) stored at −190°C in liquid nitrogen vapor phase freezers, 
along with corresponding formalin-fixed paraffin-embedded 
(FFPE) tissue blocks, blood specimens (1 mL aliquots of buffy 
coats, plasma/serum, and viable lymphocytes), genomic DNA, 
urine, and saliva. In addition, BRCF has established an elec-
tronic inventory system utilizing barcoding for sample identifi-
cation, inventory tracking, and location (freezer number, shelf 
number, container number, and cell location) and annotating 
samples with basic demographic and clinical information. 
There is also a modular web-based software tool designed for 
BRCF to support operations that optimize the process of 
requesting and billing for biorepository services.
The ability to link each specimen with data from C3OD 
enhances the value of each sample and reduces the amount of 
time needed to identify patients that match the researcher’s 
request criteria. To fulfill requests, the BRCF submits a project 
review to the DAC. The DAC will review the project and con-
firm use of identified data from C3OD will be used only for 
identifying patients as needed for the request and all appropri-
ate IRB approvals from BRCF are received. Data Access 
Committee approves or disapproves the use of C3OD for the 
request. If approved, specimen identification can proceed. The 
BRCF data administrator interacts with C3OD to access clini-
cal information. After generating a list of patients that match 
specified criteria, the BRCF data administrator determines 
whether the BRCF possesses the requested specimens, and 
C3OD specifies the counts of sample available for the requested 
sample type. The BRCF administrator also performs a cross 
verification with electronic health records (EHR) to confirm 
the list of patients—this is a spot check for a second verifica-
tion, and the BRCF delivers requested samples redacted of 
Figure 1. C3OD architecture. C3OD indicates Curated Cancer Clinical Outcomes Database; DAC, Data Access Committee; IRB, institutional review 
board; EMR, electronic medical record; HIPAA, health insurance portability and accountability act; PHI, protected health information; SAS, SAS Institute 
– Developer of Analytical software.
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protected health information to the researcher. An overview of 
this process is shown in Figure 2. Most requests are for the 
actual sample, not identified patient information, thus this pro-
cess minimizes the number of people who need access to iden-
tifiable information. Under C3OD, EHR data is refreshed as 
needed and as often as daily, whereas Tumor registry data is 
refreshed once a month and biospecimen inventory informa-
tion is updated once a week.
Results
It is quite easy for the Informatics team to communicate with 
data managers as they are dealing with 3 to 4 managers at any 
given time who are fulfilling the BRCF requests. This also helps 
the informatics team to quickly update or tweak the data struc-
ture during the course of system updates that may occur at the 
source system. C3OD allows a more narrowed search of clinical 
criteria before moving to the final review of patient eligibility. 
Once a list of patients with basic tumor characteristics is created 
and before releasing samples to a researcher, the BRCF data 
managers will review additional information within the BRCF 
inventory system to correlate the collection date and EHR with 
final eligibility provided by the researcher, including but not 
limited to treatment status and disease status at the time of col-
lection. C3OD has significantly reduced redundancy in the 
annotation of clinical data linked to biospecimen samples. 
Improving annotation has been a topic of attraction, which adds 
value to the samples that have been collected over a period of 
time. To utilize these samples efficiently, BRCF had to corrobo-
rate sample information with C3OD data elements. Prior to 
C3OD, manual clinical annotation by the BRCF data managers 
included disease diagnosis, staging, survival status, and other 
key data elements related to the patient, but more detailed 
information related to treatment and basic medical history is 
frequently needed. With C3OD, time to extract and annotate 
this information for each registered patient is essentially auto-
mated and allows access to details not previously annotated due 
to manual hours needed for each patient data extraction. In 
2018, 10 of 51 projects (20%) submitted to the BRCF utilized 
C3OD in some fashion to complete the request. Some of the 
most common requests are described below. Since inception of 
C3OD, BRCF has utilized C3OD to complete approximately 
25% of the data request that initiated through BRCF.
Request 1
In the first of the 3 C3OD use-cases discussed in this report, 
investigators were interested in identifying ovarian cancer 
patients with high-grade serous disease with available FFPE 
tumor tissue and plasma samples banked within the BRCF.
A C3OD query using tumor registry data identified 504 
patients (Morphology-Histology & Behavior ICD-O-3: 
[“8441” OR “8460” OR “8461”] and Primary Site: [“C569” OR 
“C482” OR “C481” OR “C570”]). From those patients, 193 
matched with records in the BRCF specimen registry. Utilizing 
only our BRCF inventory system, we identified 328 ovarian 
cancer patients with available plasma samples. In the absence 
of C3OD, each patient’s EHR record would need to be 
reviewed to confirm the final histological diagnosis (high grade 
serous). C3OD enabled us to focus on the 193 and quickly nar-
row that down to those with annotated data available from the 
tumor registry before pulling FFPE for review. Electronic 
health records review to confirm qualification for the request 
requires approximately 10 minutes per patient. Thus, narrow-
ing the available cohort of samples from 328 to 193 equates to 
over 22 hours of time saved.
Request 2
The second use-case involved the identification of patients with a 
rare diagnosis: inverted papilloma, sinonasal squamous cell carci-
noma, sinonasal squamous cell carcinoma from inverted papil-
loma, or sinonasal undifferentiated carcinoma. A C3OD query 
Figure 2. Biospecimen clinical annotation workflow. C3OD indicates 
Curated Cancer Clinical Outcomes Database; DAC, Data Access 
Committee.
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from the tumor registry data identified 253 with malignancies in 
the primary sites discussed in person with the researcher (ICD-O-
3: C30.0, C31.0, C31.1, C31.2, C31.3, C31.9, C12.9). From those 
patients, 42 had matched records in the BRCF inventory system, 
and of those, 6 had frozen tissue available in the biorepository. 
C3OD enabled the BRCF data manager to quickly confirm the 
availability of a specific subset of tissue for the researcher.
Request 3
The final use-case involved the identification of at least 50 fro-
zen plasma samples for benign colorectal conditions. The 
BRCF patient registration focuses on patients with malignant 
disease; thus, annotation within the BRCF inventory system of 
non-malignancy is limited. A C3OD query of EHR data for 
89 different ICD diagnosis codes related to benign colorectal 
conditions resulted in 13 699 unique patients. From those 
patients, 492 matched with records in the BRCF specimen 
registry with frozen plasma available. The BRCF provided the 
customer with 67 samples to meet the needs of the study.
As demonstrated in Table 1, we see that significant time and 
cost saving are utilizing a data-warehouse such as C3OD 
which is populated and curated to house quality data.
Discussion
C3OD improves efficiency and reduces the cost of fulfilling com-
plex specimen requests within the BRCF. Without C3OD, the 
BRCF staff would be limited to only diagnosis information pro-
vided at the time of collection and limited historical patient infor-
mation. Furthermore, each patient’s EHR would have to be 
reviewed to determine whether they meet the study criteria. C3OD 
quickly creates a list of patients that match many specific criteria 
and allows the BRCF staff to narrow down the number of records 
to review. Once a list of patients is created using C3OD, estimated 
time to confirm final qualifications with information in EHR is 5 
to 10 minutes per patient. Our working group continues refine-
ment of C3OD to improve the specificity of queries. Standardization 
in collecting data and extracting discrete data from unstructured 
documents are key areas of C3OD improvement in the future.
Acknowledgements
We would like to extend our gratitude to Drs Roy A. Jensen 
and Andrew K. Godwin for the indispensable guidance and 
advice they provided on the design and development of C3OD.
Author Contributions
D.P.M. and E.S. oversaw all aspects of drafting, revision, and 
final approval of the manuscript. J.T. and M.P. lead the process 
of drafting and revising the manuscript. J.H. contributed to the 
C3OD usability survey and participated in the drafting and 
revising of the manuscript. D.S. and J.W. assisted in the devel-
opment and reliability testing of C3OD, participated in the 
drafting, and revising the manuscript. M.P. and A.K.G. made 
significant intellectual contributions regarding the develop-
ment and design of C3OD and participated in the drafting and 
revising of the manuscript. B.G. and D.C.K. participated in the 
drafting and revising of the manuscript. R.A.J. and M.S.M. 
provided advice on design, development, and operational issues 
related to C3OD implementation and participated in the 
drafting and revising of the manuscript.
ORCID iD
Dinesh Pal Mudaranthakam  https://orcid.org/0000-0001- 
9767-1158
Supplemental Material
Supplemental material for this article is available online.
RefeRenCeS
1. Jacobson RS, Becich MJ, Bollag RJ, et al. A federated network for translational 
cancer research using clinical data and biospecimens. Cancer Res. 2015;75: 
5194-5201.
2. Liu A. Developing an institutional cancer biorepository for personalized medi-
cine. Clin Biochem. 2014;47:293-299.
3. Campbell LD, Astrin JJ, DeSouza Y, et al. The 2018 revision of the ISBER best 
practices: summary of changes and the editorial team’s development process. Bio-
preserv Biobank. 2018;16:3-6.
4. Office of Biorepositories and Biospecimen Research, NCI, NIH, U.S. Depart-
ment of Health and Human Services. NCI Best Practices for Biospecimen Resources. 
https://biospecimens.cancer.gov/bestpractices/2016-NCIBestPractices.pdf. 
Accessed November 5, 2018.
5. Kelly SM, Wiehagen LT, Schumacher PE, Dhir R. Methods to improve 
sustainability of a large academic biorepository. Biopreserv Biobank. 2017;15: 
31-36.
6. Roden DM, Pulley JM, Basford MA, et al. Development of a large-scale de-
identified DNA biobank to enable personalized medicine. Clin Pharmacol Ther. 
2008;84:362-369.
7. Bourgeois FT, Avillach P, Kong SW, et al. Development of the precision link 
biobank at Boston Children’s Hospital: challenges and opportunities. J Pers Med. 
2017;7:E21.
8. Foran DJ, Chen W, Chu H, et al. Roadmap to a comprehensive clinical data 
warehouse for precision medicine applications in oncology. Cancer Inform. 
2017;16:1176935117694349.
9. Mudaranthakam DP, Thompson J, Hu J, et al. A Curated Cancer Clinical Out-
comes Database (C3OD) for accelerating patient recruitment in cancer clinical 
trials. JAMIA Open. 2018;1:166-171.
Table 1. Time and cost saving for BRCF team utilizing C3OD.
TIME COST (SAlARIED TIME, $20/HR)
 BEFORE C3OD AFTER C3OD BEFORE C3OD AFTER C3OD
Request 1 54.67 hours 32.17 hours US$1093.40 US$643.40
Request 2 Not possible Minimal—<1 hour Unknown <US$20
Request 3 Not possible 11.17 hours Unknown US$224
Abbreviations: BRCF, Biospecimen Repository Core Facility; C3OD, Curated Cancer Clinical Outcomes Database.
